drug

LTG-321

2 stories · latest Sep 3, 2026

Timeline

Latigo reports Q2 2026 results, NEJM publication for onzotrigine, and completed IPO

Sep 3Quarterly updateLatigo Biotherapeutics

Latigo Biotherapeutics prices IPO at $18 per share on Nasdaq

Aug 7FinancingLatigo Biotherapeutics